GSK partners with Flagship Pioneering in a $7.2bn deal, focusing on respiratory and immunology treatments with potential for 10 new drug projects.
GSK partners with US biotech firm Flagship Pioneering in a $7.2bn deal, investing $150m upfront for a focus on respiratory and immunology treatments. The collaboration aims to explore up to 10 new drug projects, with each eligible for up to $720m in milestones if successful. The partnership leverages GSK's expertise and development capabilities with Flagship's ecosystem of bioplatform companies.
July 29, 2024
4 Articles